Brain-Oriented Strategies for Neuroprotection of Asphyxiated Newborns in the First Hours of Life

Pediatr Neurol. 2023 Jun:143:44-49. doi: 10.1016/j.pediatrneurol.2023.02.015. Epub 2023 Mar 2.

Abstract

Perinatal asphyxia represents the first cause of severe neurological disabilities and the second cause of neonatal death in term-born babies. Currently, no treatment can prevent immediate cell death from necrosis, but some therapeutic interventions, such as therapeutic hypothermia (TH), can reduce delayed cell death from apoptosis. TH significantly improves the combined outcome of mortality or major neurodevelopmental disability, but the number of patients to be treated is 7 to get 1 child with no adverse neurological outcome. The aim of this educational review is to analyze the other care strategies to be implemented to improve the neurological outcome of children with hypoxic ischemic encephalopathy (HIE). Hypocapnia, hypoglycemia, pain control, and functional brain monitoring are recognized as appropriate approaches to improve outcome in critically ill infants with HIE. Pharmacologic neuroprotective adjuncts are currently under investigation. New drugs such as allopurinol and melatonin seem to provide positive effects although more randomized controlled trials are required to establish the effective therapeutic scheme. In the meantime, sustaining the respiratory, metabolic, and cardiovascular system during TH can be a valuable aid in managing and treating the patient with HIE in an optimal way.

Keywords: Hypoxia-ischemia; Hypoxic-ischemic encephalopathy; Neuroprotection; Newborn infant; Therapeutic hypothermia.

Publication types

  • Review

MeSH terms

  • Asphyxia Neonatorum* / complications
  • Asphyxia Neonatorum* / therapy
  • Brain
  • Child
  • Humans
  • Hypothermia, Induced* / adverse effects
  • Hypoxia-Ischemia, Brain* / therapy
  • Infant
  • Infant, Newborn
  • Infant, Newborn, Diseases* / therapy
  • Neuroprotection
  • Stroke* / etiology